» Articles » PMID: 17658592

An Electronic Nose in the Discrimination of Patients with Asthma and Controls

Overview
Date 2007 Jul 31
PMID 17658592
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Exhaled breath contains thousands of volatile organic compounds (VOCs) that could serve as biomarkers of lung disease. Electronic noses can distinguish VOC mixtures by pattern recognition.

Objective: We hypothesized that an electronic nose can discriminate exhaled air of patients with asthma from healthy controls, and between patients with different disease severities.

Methods: Ten young patients with mild asthma (25.1 +/- 5.9 years; FEV(1), 99.9 +/- 7.7% predicted), 10 young controls (26.8 +/- 6.4 years; FEV(1), 101.9 +/- 10.3), 10 older patients with severe asthma (49.5 +/- 12.0 years; FEV(1), 62.3 +/- 23.6), and 10 older controls (57.3 +/- 7.1 years; FEV(1), 108.3 +/- 14.7) joined a cross-sectional study with duplicate sampling of exhaled breath with an interval of 2 to 5 minutes. Subjects inspired VOC-filtered air by tidal breathing for 5 minutes, and a single expiratory vital capacity was collected into a Tedlar bag that was sampled by electronic nose (Cyranose 320) within 10 minutes. Smellprints were analyzed by linear discriminant analysis on principal component reduction. Cross-validation values (CVVs) were calculated.

Results: Smellprints of patients with mild asthma were fully separated from young controls (CVV, 100%; Mahalanobis distance [M-distance], 5.32), and patients with severe asthma could be distinguished from old controls (CVV, 90%; M-distance, 2.77). Patients with mild and severe asthma could be less well discriminated (CVV, 65%; M-distance, 1.23), whereas the 2 control groups were indistinguishable (CVV, 50%; M-distance, 1.56). The duplicate samples replicated these results.

Conclusion: An electronic nose can discriminate exhaled breath of patients with asthma from controls but is less accurate in distinguishing asthma severities.

Clinical Implication: These findings warrant validation of electronic noses in diagnosing newly presented patients with asthma.

Citing Articles

Breathomics: may it become an affordable, new tool for early diagnosis of non-small-cell lung cancer? An exploratory study on a cohort of 60 patients.

Brascia D, Iaco G, Panza T, Signore F, Carleo G, Zang W Interdiscip Cardiovasc Thorac Surg. 2024; 39(3).

PMID: 39226187 PMC: 11379464. DOI: 10.1093/icvts/ivae149.


Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study.

Djukanovic R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J Am J Respir Crit Care Med. 2024; 210(3):288-297.

PMID: 38635834 PMC: 11348961. DOI: 10.1164/rccm.202310-1730OC.


Use of Sensor Array Analysis to Detect Ovarian Cancer through Breath, Urine, and Blood: A Case-Control Study.

Angioli R, Santonico M, Pennazza G, Montera R, Luvero D, Gatti A Diagnostics (Basel). 2024; 14(5).

PMID: 38473033 PMC: 10930654. DOI: 10.3390/diagnostics14050561.


Exhaled Breath Analysis Detects the Clearance of from the Airways of Children with Cystic Fibrosis.

Seidl E, Licht J, de Vries R, Ratjen F, Grasemann H Biomedicines. 2024; 12(2).

PMID: 38398033 PMC: 10887307. DOI: 10.3390/biomedicines12020431.


Breath Analysis for Lung Cancer Early Detection-A Clinical Study.

Jia Z, Thavasi V, Venkatesan T, Lee P Metabolites. 2023; 13(12).

PMID: 38132879 PMC: 10745549. DOI: 10.3390/metabo13121197.